- Home
- XENE vs NAMS Comparison
XENE vs NAMS Comparison
Compare XENE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- NAMS
- Stock Information
- Founded
- XENE 1996
- NAMS 2019
- Country
- XENE Canada
- NAMS Netherlands
- Employees
- XENE N/A
- NAMS N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- NAMS Health Care
- Exchange
- XENE Nasdaq
- NAMS Nasdaq
- Market Cap
- XENE 2.4B
- NAMS 2.5B
- IPO Year
- XENE 2014
- NAMS N/A
- Fundamental
- Price
- XENE $32.21
- NAMS $21.54
- Analyst Decision
- XENE Strong Buy
- NAMS Strong Buy
- Analyst Count
- XENE 11
- NAMS 8
- Target Price
- XENE $54.82
- NAMS $42.88
- AVG Volume (30 Days)
- XENE 1.5M
- NAMS 976.0K
- Earning Date
- XENE 08-07-2025
- NAMS 08-06-2025
- Dividend Yield
- XENE N/A
- NAMS N/A
- EPS Growth
- XENE N/A
- NAMS N/A
- EPS
- XENE N/A
- NAMS N/A
- Revenue
- XENE $7,500,000.00
- NAMS $47,140,000.00
- Revenue This Year
- XENE N/A
- NAMS N/A
- Revenue Next Year
- XENE $253.71
- NAMS N/A
- P/E Ratio
- XENE N/A
- NAMS N/A
- Revenue Growth
- XENE N/A
- NAMS 586.97
- 52 Week Low
- XENE $26.74
- NAMS $14.06
- 52 Week High
- XENE $46.00
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- XENE 50.43
- NAMS 64.18
- Support Level
- XENE $31.22
- NAMS $17.97
- Resistance Level
- XENE $33.51
- NAMS $22.15
- Average True Range (ATR)
- XENE 1.24
- NAMS 0.92
- MACD
- XENE 0.06
- NAMS 0.35
- Stochastic Oscillator
- XENE 40.88
- NAMS 86.50
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.